With 100% national capital and 47-year history of leadership in the local industry, Aché is among the most important Brazilian pharmaceutical groups.
Supported by a team of about 3.803 employees, Aché manufactures and promotes 279 drugs, in 689 different versions, among RX, OTC and generic products. The excellence of a sales force of over 1.900 medical representatives – which is considered the best in the Brazilian market has allowed Aché to maintain its first position in prescription generation, confirming itself as the favorite laboratory for Brazilian physicians.
Investing in portfolio renewal is an essential part of the sustainable growth strategy devised by Aché over the last years. To reach the high number of launches in 2013 – 32 in the year – and keep the growth perspectives for the future, the Company allocated in the period R$ 54.9 million to research and development.Results for 2014 and the next years will be incremented by the 170 projects in the company’s pipeline.
Licensing agreements allow consolidating Aché’s brands in 11 countries in the Americas and Africa, composing a portfolio of over 40 pharmaceutical formulations.